Alembic sets FY27 revenue growth target at low double digits
Q4 FY26 conference call transcript confirms guidance for low double-digit revenue growth, R&D spend of ₹750-800 crore, and margin improvement.
What's new
- Transcript of Q4 FY26 earnings call confirms FY27 guidance.
- Management expects low double-digit revenue growth and margin improvement.
- No new material information beyond the live call.
Why it matters
The transcript is a routine record of already-disclosed guidance. Investors already heard the key points during the live call; the filing adds no new data. What matters is whether management delivers on the growth and margin targets laid out.
What we're watching
- Execution on US branded business and peptide pipeline
- Ability to expand margins in FY27
- Quarterly progress against the low double-digit growth target
The full read
Alembic Pharmaceuticals' Q4 FY26 earnings call transcript confirms management's FY27 outlook: low double-digit revenue growth, R&D spend of ₹750-800 crore, and expectations of margin improvement. The call also covered the US branded business and peptide pipeline in Q&A. However, the transcript is a procedural filing — the core information was disseminated during the live call on May 15, 2026. For investors, the open question is whether Alembic can execute on its guidance, not what the transcript says today.